Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Multiple Ascending Dose Study of ALXN1210 in PNH
2015-002674-20Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Primary endpoint: Change in LDH levels from baseline to Day 253. Started Aug 2015; status: completed.
02
Drugs
ravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2015-002674-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002674-20.